MedDataX Logo

IV Paracetamol Versus IV Dexketoprofen in Dysmenorrhea

NCT ID: NCT02373514

Last Updated: 2015-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients presented with dysmenorrhea composed the study population. One gram paracetamol and 50 mg dexketoprofen in 100 ml saline with a rapid infusion were compared in ceasing dysmenorrhea in emergency department.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients over 18 years old who presented with dysmenorrhea composed the study population. Patients received pain killer within the last six hours, physical findings consistent with peritoneal irritation, allergy to the study drugs, renal or liver failure, drug addiction, pregnancy or woman with lactation and denied to give inform consent were the exclusion criteria. The pain of the study patients are measured with visual analogue scale at baseline, 15th and 30th minutes. At the end of the 30 minutes, rescue drug need is also recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dysmenorrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paracetamol

Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion

Group Type ACTIVE_COMPARATOR

Paracetamol

Intervention Type DRUG

1 gr paracetamol in 100 ml saline with rapid infusion

Dexketoprofen

Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion

Group Type ACTIVE_COMPARATOR

Dexketoprofen

Intervention Type DRUG

50 mg dexketoprofen in 100 ml saline with rapid infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paracetamol

1 gr paracetamol in 100 ml saline with rapid infusion

Intervention Type DRUG

Dexketoprofen

50 mg dexketoprofen in 100 ml saline with rapid infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perfalgan Arveles

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with dysmenorrhea
* Patients over 18 years old

Exclusion Criteria

* denied to give inform consent
* Renal or liver failure
* Allergy to the study drugs
* Receiving pain killer within the last 6 hours.
* Physical examination findings consistent with peritoneal irritation
* Pregnancy or patients with lactation
* Drug addiction
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Akdeniz University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cenker Eken

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mustafa Serinken, MD

Role: PRINCIPAL_INVESTIGATOR

Pamukkale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pamukkale University

Denizli, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cenker Eken, Medical Doctor

Role: CONTACT

Phone: 0090 532 1593948

Email: [email protected]

Mustafa Serinken, MD

Role: CONTACT

Phone: 0090 505 2991497

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mustafa Serinken, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

57051259-020/70177

Identifier Type: -

Identifier Source: org_study_id